UBS Downgrades Intra-Cellular Therapies (ITCI) to Neutral (earlier)
Tweet Send to a Friend
UBS analyst Ashwani Verma downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Buy to Neutral with a price target of $83.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
